Meeting
2013 ASCO Annual Meeting
Effect of abiraterone acetate (AA) on patient-reported pain in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel: Results of longitudinal sensitivity analyses.
Authors
Yanni Hao
Janssen Global Services, Raritan, NJ
Yanni Hao , Charles S. Cleeland , Dennis Gagnon , Derek Espindle , Arturo Molina , Ethan M. Basch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT00638690
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9618)
DOI
10.1200/jco.2013.31.15_suppl.9618
Abstract #
9618
Poster Bd #
37F
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
The potential role of frailty in modifying quality-of-life related outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel, abiraterone, enzalutamine, and radium 223.
First Author: Seungyeon Kim
Poster
2016 Genitourinary Cancers Symposium
Treatment patterns after abiraterone acetate in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302.
First Author: Thomas W. Flaig
Poster
2024 ASCO Genitourinary Cancers Symposium
LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Sumit Kumar Subudhi
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting.
First Author: Emily Nash Smyth